Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
1305 East Houston Street , San Antonio, TX, 78205, US
As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development.
Released By Scorpius BioManufacturing
A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.
What is a culture of quality, and how do you know if a biologics CDMO can earnestly make this claim?
Samir Lakhashe, Director, Bioanalytical Sciences, discusses assay categorization, the company's growing toolbox, predictions for the future, and more.
The demand for biologic drugs continues to grow at a steady 12–14% annually.
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
Clinical manufacturing of cGMP-compliant mammalian cell culture processes is a complex and resource-intensive effort that presents several challenges.
Biologics process development is an active undertaking that seeks continuous improvement along the entire length of the drug development timeline.
A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle.
The value biologics CDMOs provide their innovator customers has changed radically in recent years, presenting new questions that must be answered.
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.
When selecting a biologics CDMO partner—whether you need mammalian or microbial capabilities—the decision-making process follows a similar process.
Why Fina Biosolutions partnered with Scorpius Biomanufacturing for cGMP production of Ecocrm® (CRM197)
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.
The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, and more.
Flexible, responsive, customized services for taking a program from R&D into the clinic, using American facilities and American sourced materials and equipment.
Delivering consistent and scalable mammalian-derived products, Scorpius uses its American facilities to advance your drug from R&D to the clinic and beyond.
Scorpius’ team has extensive experience in E. coli microbial biomanufacturing, including hard-to-work-with inclusion bodies.
Utilizing American-made equipment and reagents, Scorpius develops custom assays to profile your molecule and test your clinical trial samples.
Process development & cGMP contract manufacturing for biologics and cell therapies.
New programs combine rapid microbiology testing and NGS characterization to shorten biologics development timelines.
By: Charlie Sternberg
License variation supports early-phase GMP manufacture at Nottingham facility.
The strategic collaboration was agreed upon with an undisclosed biopharmaceutical company.
By: Patrick Lavery
Large stainless-steel projects are rising, but pipeline demand is increasingly moving toward smaller, more flexible manufacturing models.
By: Dan Stanton
The move expands Axiom’s manufacturing and clinical development capabilities.
The agreement extends manufacturing commitments through 2033 and pushes Samsung Biologics’ cumulative contract value above $21.9 billion.
The company hopes this will expand access to advanced therapeutics manufacturing not only in Australia, but also across Asia-Pacific.
The 21,000-square-foot facility will train students for careers in aseptic and sterile pharmaceutical manufacturing.
The CDMO is adding new property, aseptic fill-finish lines, packaging capacity, and analytical capabilities at its Caponago site near Milan.
Formulation, manufacturing and delivery strategies for high-dose biologics administered subcutaneously.
By: Jim Huang, Shaukat Ali
Highly potent compounds are reshaping CDMO expectations, from early risk assessment to closed, automated containment facilities.
Collaboration aims to support manufacturing readiness for next-generation bioprocessing technologies.
Independent testing shows barrier labels help protect biologics and biosimilars.
WuXi Biologics gains non-exclusive access to selected HiCB platform technologies.
The 3,500-square-meter BIO CITY III facility adds up to 20 cGMP manufacturing lines for cell therapies and personalized medicine.
By: Tim Wright
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
